Acknowledgement
This paper was supported by Konkuk University in 2021.
References
- Arepalli, S. and Kaiser, P.K. (2021). Pipeline therapies for neovascular age related macular degeneration. Int. J. Retina Vitreous 7, 55.
- Birch, J. and Gil, J. (2020). Senescence and the SASP: many therapeutic avenues. Genes Dev. 34, 1565-1576. https://doi.org/10.1101/gad.343129.120
- Cabral de Guimaraes, T.A., Daich Varela, M., Georgiou, M., and Michaelides, M. (2022). Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br. J. Ophthalmol. 106, 297-304. https://doi.org/10.1136/bjophthalmol-2020-318452
- Chae, J.B., Jang, H., Son, C., Park, C.W., Choi, H., Jin, S., Lee, H.Y., Lee, H., Ryu, J.H., Kim, N., et al. (2021). Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration. Geroscience 43, 2809-2833. https://doi.org/10.1007/s11357-021-00457-4
- Chang, J., Wang, Y., Shao, L., Laberge, R.M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N.E., Ding, S., Feng, W., et al. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78-83. https://doi.org/10.1038/nm.4010
- Chen, Y., Bedell, M., and Zhang, K. (2010). Age-related macular degeneration: genetic and environmental factors of disease. Mol. Interv. 10, 271-281. https://doi.org/10.1124/mi.10.5.4
- Childs, B.G., Durik, M., Baker, D.J., and van Deursen, J.M. (2015). Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424-1435. https://doi.org/10.1038/nm.4000
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire, M.G., Martin, D.F., Ying, G.S., Jaffe, G.J., Daniel, E., Grunwald, J.E., Toth, C.A., Ferris, F.L., 3rd, and Fine, S.L. (2016). Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123, 1751-1761. https://doi.org/10.1016/j.ophtha.2016.03.045
- Cox, J.T., Eliott, D., and Sobrin, L. (2021). Inflammatory complications of intravitreal anti-VEGF injections. J. Clin. Med. 10, 981.
- Crespo-Garcia, S., Tsuruda, P.R., Dejda, A., Ryan, R.D., Fournier, F., Chaney, S.Y., Pilon, F., Dogan, T., Cagnone, G., Patel, P., et al. (2021). Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab. 33, 818-832. e7. https://doi.org/10.1016/j.cmet.2021.01.011
- Di Micco, R., Krizhanovsky, V., Baker, D., and d'Adda di Fagagna, F. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22, 75-95. https://doi.org/10.1038/s41580-020-00314-w
- Ding, X., Patel, M., and Chan, C.C. (2009). Molecular pathology of age-related macular degeneration. Prog. Retin. Eye Res. 28, 1-18. https://doi.org/10.1016/j.preteyeres.2008.10.001
- Dubik, N. and Mai, S. (2020). Lamin A/C: function in normal and tumor cells. Cancers (Basel) 12, 3688.
- Falavarjani, K.G. and Nguyen, Q.D. (2013). Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond.) 27, 787-794. https://doi.org/10.1038/eye.2013.107
- Gandhi, L., Camidge, D.R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C.L., McKeegan, E.M., Litvinovich, E., Hemken, P.M., et al. (2011). Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916. https://doi.org/10.1200/JCO.2010.31.6208
- Han, Z., Liang, J., Li, Y., and He, J. (2019). Drugs and clinical approaches targeting the antiapoptotic protein: a review. Biomed Res. Int. 2019, 1212369.
- Handa, J.T., Bowes Rickman, C., Dick, A.D., Gorin, M.B., Miller, J.W., Toth, C.A., Ueffing, M., Zarbin, M., and Farrer, L.A. (2019). A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat. Commun. 10, 3347.
- Huang, W., Hickson, L.J., Eirin, A., Kirkland, J.L., and Lerman, L.O. (2022). Cellular senescence: the good, the bad and the unknown. Nat. Rev. Nephrol. 18, 611-627. https://doi.org/10.1038/s41581-022-00601-z
- Kim, S. and Kim, C. (2021). Transcriptomic analysis of cellular senescence: one step closer to senescence atlas. Mol. Cells 44, 136-145. https://doi.org/10.14348/molcells.2021.2239
- Kipps, T.J., Eradat, H., Grosicki, S., Catalano, J., Cosolo, W., Dyagil, I.S., Yalamanchili, S., Chai, A., Sahasranaman, S., Punnoose, E., et al. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymphoma 56, 2826-2833. https://doi.org/10.3109/10428194.2015.1030638
- Kirkland, J.L. and Tchkonia, T. (2015). Clinical strategies and animal models for developing senolytic agents. Exp. Gerontol. 68, 19-25. https://doi.org/10.1016/j.exger.2014.10.012
- Kozlowski, M.R. (2012). RPE cell senescence: a key contributor to age-related macular degeneration. Med. Hypotheses 78, 505-510. https://doi.org/10.1016/j.mehy.2012.01.018
- Lee, G. (2022). Cellular senescence: the villain of metabolic disease? Mol. Cells 45, 531-533. https://doi.org/10.14348/molcells.2022.0084
- Lock, R., Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Maris, J.M., Keir, S.T., Wu, J., et al. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 1181-1189. https://doi.org/10.1002/pbc.21433
- Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. Cell 153, 1194-1217. https://doi.org/10.1016/j.cell.2013.05.039
- Mohamad Anuar, N.N., Nor Hisam, N.S., Liew, S.L., and Ugusman, A. (2020). Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent. Front. Pharmacol. 11, 564108.
- Rudin, C.M., Hann, C.L., Garon, E.B., Ribeiro de Oliveira, M., Bonomi, P.D., Camidge, D.R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S.S., et al. (2012). Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169. https://doi.org/10.1158/1078-0432.CCR-11-3090
- Serrano, M. and Barzilai, N. (2018). Targeting senescence. Nat. Med. 24, 1092-1094. https://doi.org/10.1038/s41591-018-0141-4
- Shoemaker, A.R., Mitten, M.J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., Oleksijew, A., O'Connor, J.M., Wang, B., Frost, D.J., et al. (2008). Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res. 14, 3268-3277. https://doi.org/10.1158/1078-0432.CCR-07-4622
- Tse, C., Shoemaker, A.R., Adickes, J., Anderson, M.G., Chen, J., Jin, S., Johnson, E.F., Marsh, K.C., Mitten, M.J., Nimmer, P., et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428. https://doi.org/10.1158/0008-5472.CAN-07-5836
- de Vos, S., Leonard, J.P., Friedberg, J.W., Zain, J., Dunleavy, K., Humerickhouse, R., Hayslip, J., Pesko, J., and Wilson, W.H. (2021). Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk. Lymphoma 62, 810-818. https://doi.org/10.1080/10428194.2020.1845332
- Wilson, W.H., Tulpule, A., Levine, A.M., Dunleavy, K., Krivoshik, A.P., Hagey, A.E., Shovlin, M., Gloria, M.A., Greco, R., Xiong, H., et al. (2007). A Phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Blood 110, 1371.
- Wong, W.L., Su, X., Li, X., Cheung, C.M., Klein, R., Cheng, C.Y., and Wong, T.Y. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2, e106-e116. https://doi.org/10.1016/S2214-109X(13)70145-1